title: Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study.
abstract: Impulse control disorders such as pathological gambling (PG) are a serious and common adverse effect of dopamine (DA) replacement medication in Parkinson's disease (PD). Patients with PG have increased impulsivity and abnormalities in striatal DA, in common with behavioural and substance addictions in the non-PD population. To date, no studies have investigated the role of extrastriatal dopaminergic abnormalities in PD patients with PG. We used the PET radiotracer, [11C] FLB-457, with high-affinity for extrastriatal DA D2/3 receptors. 14 PD patients on DA agonists were imaged while they performed a gambling task involving real monetary reward and a control task. Trait impulsivity was measured with the Barratt Impulsivity Scale (BIS). Seven of the patients had a history of PG that developed subsequent to DA agonist medication. Change in [11C] FLB-457 binding potential (BP) during gambling was reduced in PD with PG patients in the midbrain, where D2/D3 receptors are dominated by autoreceptors. The degree of change in [11C] FLB-457 binding in this region correlated with impulsivity. In the cortex, [11C] FLB-457 BP was significantly greater in the anterior cingulate cortex (ACC) in PD patients with PG during the control task, and binding in this region was also correlated with impulsivity. Our findings provide the first evidence that PD patients with PG have dysfunctional activation of DA autoreceptors in the midbrain and low DA tone in the ACC. Thus, altered striatal and cortical DA homeostasis may incur vulnerability for the development of PG in PD, linked with the impulsive personality trait.
authors: Morton and Gloria Shulman Movement Disorder Unit & E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ontario, Canada.
authors: Nicola J
authors: NJ
authors: Ray
authors: Janis M
authors: JM
authors: Miyasaki
authors: Mateusz
authors: M
authors: Zurowski
authors: Ji Hyun
authors: JH
authors: Ko
authors: Sang Soo
authors: SS
authors: Cho
authors: Giovanna
authors: G
authors: Pellecchia
authors: Francesca
authors: F
authors: Antonelli
authors: Sylvain
authors: S
authors: Houle
authors: Anthony E
authors: AE
authors: Lang
authors: Antonio P
authors: AP
authors: Strafella
mesh_terms: D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000009:adverse effects*; D005715:Gambling / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000378:metabolism; D006706:Homeostasis / Q000502:physiology*; D006801:Humans; D008636:Mesencephalon / Q000000981:diagnostic imaging*; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000523:psychology; D049268:Positron-Emission Tomography; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D012457:Salicylamides
chemical_list: D018491:Dopamine Agonists; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D012457:Salicylamides; C065065:FLB 457; D004298:Dopamine